Olga Renner

Prof. Dr. Olga Renner


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
APAlban Piotrowsky
Alban Piotrowsky
Markus BurkardMarkus Burkard
Markus Burkard
KHKatharina Hammerschmidt
Katharina Hammerschmidt
HRHannah K. Ruple
Hannah K. Ruple
PNPia Nonnenmacher
Pia Nonnenmacher
Sascha VenturelliSascha Venturelli
Sascha Venturelli
Several studies have demonstrated, both in vitro and in animal models, the anti-tumor efficacy of high-dose ascorbate treatment against a variety of tumor entities, including glioblastoma, the most common and aggressive primary malignant brain tumor. The aim of this study was to investigate the effects of high-dose ascorbate as well as dehydroascorbic acid on human glioblastoma cell lines and to evaluate different treatment conditions for the combined administration of ascorbate with magnesium (Mg2+) and iron (Fe3+). Intracellular levels of reactive oxygen species and the induction of cell death following ascorbate treatment were also investigated. We demonstrated high cytotoxicity and antiproliferative efficacy of high-dose ascorbate in human glioblastoma cells, whereas much weaker effects were observed for dehydroascorbic acid. Ascorbate-induced cell death was independent of apoptosis. Both the reduction in cell viability and the ascorbate-induced generation of intracellular reactive oxygen species could be significantly increased by incubating the cells with Fe3+ before ascorbate treatment. This work demonstrates, for the first time, an increase in ascorbate-induced intracellular ROS formation and cytotoxicity in human glioblastoma cells by pre-treatment of the tumor cells with ferric iron, as well as caspase-3 independence of cell death induced by high-dose ascorbate. Instead, the cell death mechanism caused by high-dose ascorbate in glioblastoma cells shows evidence of ferroptosis. The results of the present work provide insights into the efficacy and mode of action of pharmacological ascorbate for the therapy of glioblastoma, as well as indications for possible approaches to increase the effectiveness of ascorbate treatment.

31 December 2024 in Heliyon
Verified
Journal Article
Open access
APAlban Piotrowsky
Alban Piotrowsky
MBMarkus Burkard
Markus Burkard
HSHendrik Schmieder
Hendrik Schmieder
SVSascha Venturelli
Sascha Venturelli
OROlga Renner
Olga Renner
Luigi MarongiuLuigi Marongiu
Luigi Marongiu
The pancreatic ductal adenocarcinoma (PDAC) is among the deadliest tumor diseases worldwide. While treatment options have generally become more diverse, little progress has been made in the treatment of PDAC and the median survival time for patients with locally advanced PDAC is between 8.7 and 13.7 months despite treatment. The aim of this review was to explore the therapeutic potential of complementing standard therapy with natural or synthetic forms of vitamins A, C, and D.

22 October 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
Dimitri BarskiDimitri Barski
Dimitri Barski
PFPatrick Finzer
Patrick Finzer
KGKlaus Golka
Klaus Golka
OROlga Renner
Olga Renner
RWRalph M. Wirtz
Ralph M. Wirtz
TOThomas Otto
Thomas Otto
(1) Background: Recurrent urinary tract infections (rUTIs) are common among peri- and postmenopausal women, partly due to hormonal changes that disrupt the vaginal microbiota. A reduction in Lactobacillus dominance is associated with increased risk of rUTI. Although antibiotics remain the standard of care, their use contributes to the emergence of multidrug-resistant pathogens. Probiotics may offer a non-antibiotic alternative; however, clinical evidence remains limited. (2) Methods: The VaMirUTI study is a prospective, monocentric, non-randomized cohort investigating the combined effect of oral probiotics and vaginal estriol on vaginal and urinary microbiota in peri- and postmenopausal women with recurrent UTIs. The primary endpoints are (i) change in Lactobacillus dominance at 3 months and (ii) UTI recurrence at 12 months. A total of 100 women (70 rUTI, 30 controls) will be followed for up to 12 months. Vaginal swabs and urine samples will be collected at baseline, during UTI episodes, and at study completion. Vaginal microbiota composition will be analyzed by 16S rRNA gene sequencing. (3) Results: This protocol outlines the study design and methodology. The primary outcome is the change in vaginal Lactobacillus dominance following the intervention. Secondary outcomes include UTI recurrence rates and the identification of microbiota signatures associated with rUTI. (4) Conclusions: The VaMirUTI study will clarify the relationship between vaginal microbiota, oral probiotic supplementation, and rUTI in menopausal women, potentially informing future non-antibiotic preventive strategies.